(+)-VINCRISTINE
Adnexal Diseases
Xiaoxiang ChenSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Adnexal Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclobenzaprine Christiana Care Health Services | Phase 4 | B |
Trabectedin Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | B |
DEXAMETHASONE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | B |
Catequentinib Xiaoxiang Chen | Phase 2 | CCC |
Olaparib Xiaoxiang Chen | Phase 2 | CCC |
Irinotecan Xiaoxiang Chen | Phase 2 | CCC |
Niraparib Xiaoxiang Chen | Phase 2 | CCC |
89zr-mmot0530a University Medical Center Groningen | Phase 1 | CC |
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →